Therapy Services, University Hospitals Birmingham NHS Foundation Trust, Mindelsohn Way, Birmingham, UK.
Institute of Inflammation and Ageing, The University of Birmingham, Edgbaston, Birmingham, UK.
Nat Commun. 2024 Jul 31;15(1):6447. doi: 10.1038/s41467-024-50805-z.
Ventilator-associated pneumonia (VAP) affects up to 20% of critically ill patients and induces significant antibiotic prescription pressure, accounting for half of all antibiotic use in the ICU. VAP significantly increases hospital length of stay and healthcare costs yet is also associated with long-term morbidity and mortality. The diagnosis of VAP continues to present challenges and pitfalls for the currently available clinical, radiological and microbiological diagnostic armamentarium. Biomarkers and artificial intelligence offer an innovative potential direction for ongoing future research. In this Review, we summarise the pathobiological heterogeneity and diagnostic challenges associated with VAP.
呼吸机相关性肺炎（VAP）影响多达 20%的重症患者，并导致大量抗生素处方压力，占 ICU 所有抗生素使用的一半。VAP 显著增加了住院时间和医疗保健成本，但也与长期发病率和死亡率相关。目前临床、影像学和微生物学诊断工具在诊断 VAP 时仍然存在挑战和陷阱。生物标志物和人工智能为正在进行的未来研究提供了创新的潜在方向。在这篇综述中，我们总结了 VAP 相关的病理生物学异质性和诊断挑战。
